ARCHIVES

Transplant Is Viable Option For HIV+ Patients, Study Finds

This article is from The Cancer Letter archive.

Vol. 28 No. 2 | February 25, 2005

Download PDF Visit The Full Archive

Related Articles

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

September 8, 2006

Orlando Health President Mark Rohl We Opted For A Florida-Centric Strategy

January 10, 2014

Advisors Approve NCI Plan To Contract For Early Clinical Trials Of Imaging Agents.

March 31, 2000

Pathology Review Confirms Reserpine As Carcinogen

March 14, 1980

ORI Clears Los Angeles Physician Of Misconduct In NSABP Participation

June 16, 1995

Moffitt, Ohio State Form Network, Invite Major Cancer Centers to Join

May 30, 2014